Member Info for HideInPlainSight

This IPO'd at £23m and is now valued at £6m with all the progress... they've nearly got the market cap covered with grant funding let alone being the only pure-play longevity biotech listed in Europe!

My first target is 3.5p to get back to a £15m valuation. That seems the low end of fair value to me.

And my bet is it will stay liquid long enough to get to gas exchange approval (raising funds to get there) and then we're talking a much more exciting proposition

Consider me braced. Expecting to have a few ups and downs after the results and in the fundraising window... And can add to it adjust position accordingly.

But I'm liking the price, it's almost expecting zero chance of success...

In this share and I'm positive. Not because I think the upcoming results will surprise, but I just think the risk/reward is favourable now - though execution and fundraising risk is high.

Remember, the current addressable market is tiny. lung ventilation MRIs are not at all required for most hospital breathing admissions - in the specialist places that do them, I doubt they do more than a handful a week. This is advanced diagnostics for severe lung scenarios often in very ill patients.

The value to me is in the gas-exchange indication - if this is approved, my research suggestions a 50x-200x jump in potential scan volumes... this is where it gets interesting and why I think POLX is worth a punt

Fusion's NCI and FMI collaborations as powerful:

- NCI gives it external proof that its platform works on real, novel targets. This de-risks the science for partners.

- FMI gives it the firepower to keep innovating fast without cash burn.

If either of these efforts produces a validated antibody, or a licensable IP package, then Fusion has transformed its IP into a valuable asset.

...Unchallenging for a business with:

- £2m annual revenues (FY2025)

- A validated antibody platform (NCI collaboration in progress)

- A formally granted U.S. patent by next month

- Access to non-dilutive grant funding (~£1m) and £5m of infrastructure

- Existing MSAs and early traction in U.S. and diagnostics space

The £9.4m market cap prices Fusion like a revenue-only service business — with no value assigned to its now-granted U.S. patent, NCI collaboration, FMI grant/facilities, licensing potential

I believe if Fusion can execute even one commercial licensing deal, or complete validation with the NCI, then a fair valuation would likely sit at £20m–25m — 2.1–2.7x the current price.

Consider the volume too... 7 out of last 8 weeks it's been tiny.

It's not that long.

And it's a bit of a gamble.

But on a mid-term view risk/reward looks good to me.

If it goes below 0.195p then I'll reconsider and probably admit wrong call.

I suppose that's true Chesh

Invested, and down. But I'm positive... and it's not to do with BM at all. If I was invested for BM only, I'd have sold after the AGM RNS - read it back: "targeting production later this year" and more sampling to validate approach before "potentially moving to production". Distraction.

I'm in it for Baillieston and the gamble of the tax losses.

Let's get people looking forward to this imminent funded drilling campaign for gold/antimony and get excited about the exploration side again.

Looks like someone else is too with a £20k buy going through this morning!

As a relative latecomer to the party, I was thinking how much of the potential here was priced in. I thought there was much more to come and these buys seem to agree.

I've taken to validate my thoughts via AI tools and here's its take:

Looking at Great Southern Copper plc (GSCU) from today’s position—after a 200% increase in share price since February—let's break down the key points and focus on the potential event-driven trading opportunities with Phase II drilling and the company's current market cap of £28m.

Current Share Price Reaction:

200% Increase Since Late February: The market has already priced in a lot of optimism from the initial drill results (including high-grade Cu-Ag intervals) and the potential of the Mostaza deposit.

Market Cap of £28m: Despite the significant increase in share price, the market cap is still relatively low for a company in the exploration phase with promising results. For comparison, companies with similar drill results (high-grade copper-silver projects in Chile or other mining regions) can often command market caps of £50m-£150m or more depending on the scale of mineralization, historical drilling, and potential resource estimates. The current market cap suggests that GSCU may still be underappreciated, particularly if they can demonstrate a large, economic resource in the coming months.

Near-Term Drivers (Phase II Drilling Results): The key focus for the short term is Phase II drilling, particularly whether the high-grade mineralization continues to expand and whether new targets are discovered through geophysical surveys. If Phase II confirms the resource’s continuity, GSCU’s market cap could rise considerably, possibly aligning with peers in the £50m-£150m range.

Asked AI to summarise and remind me of the phase 1 drill results, here what it said 🧐

Phase One Highlights...

Phase One Drilling: Commenced in January 2025, focusing on confirming historical drilling grades and extending known mineralized zones.​

Key Findings: All eight diamond drill holes intersected visible high-grade copper mineralization, with zones up to 32.3 meters in downhole width. Notably, drill hole CNG25 DD001 intersected 20 meters of mineralization between 27m and 47m depth, confirming continuity below the historical open pit. ​

Assay Results: Drill hole CNG25 DD001 reported 20.0 meters at 3.31% Cu and 269.9 g/t Ag from 27m, including 7.0 meters at 5.72% Cu and 489.6 g/t Ag from 31m. These results significantly exceeded historical drilling outcomes.

Thanks Caravan and Ffd. I went to get quotes and got 1.88 to buy 1.71 to sell, so more like 9-10%. Still a stretch. It doesn't seem to be generating much volume either way. Hope your reasons for bullishness are correct. Convinced there's value in its assets, but the directors aren't doing a great job of selling the upside

Been in this share since early Feb, so not long. Thought it was undervalued then. -20% later and I'm not so sure. It seems too undervalued, what's going on? There seems to be minimal interest and the spread is a crazy 14%, hardly going to encourage investors/traders... Last production was underwhelming and oil has come off a bit, but surely it's worth more than current market cap?! Remaining patient.

Excellent post matml74.

That's all I could find too... Concerning.

https://www.thetimes.co.uk/article/smith-nephew-corruption-inquiry-asked-for-documents-f3f6d8qrw

Behind a paywall though.

Good steady progress...

https://twitter.com/IsaacAim/status/1480885562135482369?t=pUoitFl10ScQW1_Smqp0iw&s=19

My average is 137. Not selling. Next step is to get more info in half year report and have better understanding of the situation. Not just in regard the submission, but the other business lines too.

Perhaps a wise move since they'll not make the same false start with patch submission and will have been to crack on with other project

From 3 Nov RNS:

The Company has been advised that it would be better to run two applications relying on the same data in series rather than in parallel to avoid compromising either submission. As such, the patch 510k submission will now follow on from the graft 510k approval. This revised regulatory submission strategy also allows the Company to focus resource on a feasibility study into Peripheral Artery Disease and Critical Limb Ischemia devices for which the Company was successful in competing for Innovate UK grant finance. This exciting new project, which the Board hopes will add to the product pipeline, will be undertaken during the first quarter of 2022.